| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
11,447,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
23,616 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $0.008 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Anthera Pharmaceuticals is a biopharmaceutical company focused on advancing the development and commercialization of medicines that benefit patients with medical needs. Co. has two compounds in development, Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy intended for the treatment of patients with Exocrine Pancreatic Insufficiency, often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lowe Christopher P. |
Chief Financial Officer & CBO |
• – – |
2011-06-30 |
4 |
D |
$8.17 |
$191,995 |
D/D |
(23,500) |
65,751 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2011-06-30 |
4 |
D |
$8.17 |
$396,245 |
D/D |
(48,500) |
40,512 |
|
- |
|
| Kilfoil Georgina |
SVP, Prod. Dev. & Project Mngm |
• – – |
2011-06-30 |
4 |
D |
$8.17 |
$45,956 |
D/D |
(5,625) |
16,875 |
|
- |
|
| Hislop Colin |
Chief Medical Officer |
• – – |
2011-06-30 |
4 |
D |
$8.17 |
$142,975 |
D/D |
(17,500) |
42,967 |
|
- |
|
| Odink Debra |
VP, Pharmaceutical R&D |
• – – |
2011-06-30 |
4 |
D |
$8.17 |
$29,984 |
D/D |
(3,670) |
25,641 |
|
- |
|
| Hislop Colin |
Chief Medical Officer |
• – – |
2011-06-29 |
4 |
OE |
$0.26 |
$2,600 |
D/D |
10,000 |
60,062 |
|
- |
|
| Lowe Christopher P. |
Chief Financial Officer & CBO |
• – – |
2011-06-21 |
4 |
OE |
$0.14 |
$26,200 |
D/D |
20,000 |
87,645 |
|
- |
|
| Salzman Alan E |
10% Owner |
– – • |
2011-06-16 |
4 |
S |
$8.67 |
$26,877 |
D/D |
(3,100) |
17,611 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2011-06-15 |
4 |
AS |
$8.30 |
$124,539 |
I/I |
(15,000) |
682,125 |
|
- |
|
| Salzman Alan E |
10% Owner |
– – • |
2011-06-14 |
4 |
S |
$8.81 |
$6,158 |
D/D |
(699) |
17,621 |
|
- |
|
| Salzman Alan E |
10% Owner |
– – • |
2011-06-13 |
4 |
S |
$8.80 |
$11,440 |
D/D |
(1,300) |
17,624 |
|
- |
|
| Isaly Samuel D |
Director |
– • • |
2011-06-10 |
4 |
S |
$8.18 |
$245,400 |
I/I |
(30,000) |
3,000,000 |
|
- |
|
| Isaly Samuel D |
Director |
– • • |
2011-06-09 |
4 |
S |
$8.11 |
$300,070 |
I/I |
(37,000) |
3,030,000 |
|
- |
|
| Isaly Samuel D |
Director |
– • • |
2011-06-08 |
4 |
S |
$8.02 |
$264,660 |
I/I |
(33,000) |
3,067,000 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2011-05-31 |
4 |
GA |
$0.00 |
$0 |
I/I |
5,122 |
697,125 |
|
- |
|
| Truex Paul F |
President and CEO |
• • – |
2011-05-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,122 |
86,000 |
|
- |
|
| Salzman Alan E |
10% Owner |
– – • |
2011-05-26 |
4 |
S |
$8.60 |
$41,280 |
D/D |
(4,800) |
17,628 |
|
- |
|
| Isaly Samuel D |
Director |
– • • |
2011-05-26 |
4 |
S |
$8.53 |
$291,726 |
I/I |
(34,200) |
0 |
|
- |
|
| Isaly Samuel D |
Director |
– • • |
2011-05-25 |
4 |
S |
$8.65 |
$41,520 |
I/I |
(4,800) |
0 |
|
- |
|
| Salzman Alan E |
10% Owner |
– – • |
2011-05-25 |
4 |
S |
$8.67 |
$283,943 |
D/D |
(32,750) |
17,644 |
|
- |
|
| Salzman Alan E |
10% Owner |
– – • |
2011-05-24 |
4 |
S |
$8.42 |
$439,490 |
D/D |
(52,196) |
17,752 |
|
- |
|
| Salzman Alan E |
10% Owner |
– – • |
2011-05-23 |
4 |
S |
$8.18 |
$218,431 |
D/D |
(26,703) |
17,924 |
|
- |
|
| Salzman Alan E |
10% Owner |
– – • |
2011-05-19 |
4 |
S |
$8.03 |
$1,003,750 |
D/D |
(125,000) |
18,012 |
|
- |
|
| Isaly Samuel D |
Director |
– • • |
2011-05-18 |
4 |
S |
$8.03 |
$556,752 |
I/I |
(69,334) |
3,139,000 |
|
- |
|
| Salzman Alan E |
10% Owner |
– – • |
2011-05-17 |
4 |
S |
$8.29 |
$115,231 |
D/D |
(13,900) |
18,424 |
|
- |
|
221 Records found
|
|
Page 6 of 9 |
|
|
